NCT03170960: A trial that was reported late by Exelixis
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03170960 |
|---|---|
| Title | A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 5, 2017 |
| Completion date | July 31, 2023 |
| Required reporting date | July 30, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 19, 2025 |
| Days late | 383 |